Sponsored

Phase 1b study of Prescient Therapeutics’ (ASX: PTX) PTX-100 shows excellent safety and promising efficacy in TCL patients

December 11, 2023 01:54 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • The Phase 1b study of PTX-100 has successfully met its primary endpoints, demonstrating excellent safety.
  • The study demonstrated preliminary efficacy, exceeding that expected from standard of care, in patients with relapsed and refractory T-cell lymphomas (r/r TCL)
  • PTX plans to commence Phase 2 study in 2024.

Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased at the annual meeting of the American Society of Hematology (ASH) in California.

The study is designed to assess the safety, pharmacodynamics (PD), pharmacokinetics (PK) and preliminary efficacy profile of PTX-100 in patients with advanced malignancies. The trial focused on patients with r/r TCL.

The data surpassed the company’s expectations from both the safety and preliminary efficacy perspectives.

The company informed that the recruitment for Phase 1b study has been concluded, although multiple patients remain on study.

Presently, the company is working towards a Phase 2 trial in r/r TCL, scheduled in mid-2024. The development is expected to be a significant catalyst for the company.

PTX shares traded at AU$0.070 apiece at the time of writing on 11 December 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.